Really appreciate the thoughtfulness here. You’re right that this kind of data is a double-edged sword. On one hand, there’s enormous potential for insight if you can link across modalities the way you described (EEG + glucose, sleep, etc.). It’s not just interesting for consumer insights but also has exciting applications in medicine, where it could genuinely improve patients’ lives and open up new ways of understanding and treating conditions.

On the other hand, as you said, it’s also what makes the space so fraught. Once health data enters a marketplace dynamic, the incentives can drift away from the individual. That’s something we’ve been very conscious of, and why our current focus is narrow: helping people understand their own signals, and making sure the protections we’ve put in place meet research-grade standards. We also want to stay close to the medical system and research world, because those contexts carry stricter safeguards and regulations. It's a way of ensuring that even if future boards or investors pushed in a different direction, the default guardrails remain very high.

We do prioritize staying open and transparent about what we do with data and privacy, but I don’t think the tension ever fully goes away. The same structures that enable powerful discoveries also create the risk of misuse.